W H Anderson

Title: W H Anderson: Innovator in Cancer Treatment

Introduction

W H Anderson is a notable inventor based in Midland, MI (US). He has made significant contributions to the field of cancer treatment through his innovative work on modified antibodies. With a total of 2 patents, Anderson's inventions are paving the way for advancements in medical therapies.

Latest Patents

Anderson's latest patents focus on a family of high affinity, modified antibodies designed for cancer treatment. This invention concerns chimeric antibodies that exhibit high affinities to a high molecular weight, tumor-associated sialylated glycoprotein antigen known as TAG-72, which is of human origin. These antibodies possess high affinity animal V.sub.H and V.sub.L sequences that mediate TAG-72 binding, along with human C.sub.H and C.sub.L regions. The design of these antibodies is intended to produce significantly fewer side effects when administered to human patients, thanks to their human antibody domains. The patent also discloses the nucleotide and amino acid sequences of various idiotype sequences, as well as in vivo methods of treatment and diagnostic assays utilizing these chimeric antibodies.

Career Highlights

W H Anderson is currently associated with The Dow Chemical Company, where he continues to innovate in the field of biotechnology. His work has garnered attention for its potential to improve cancer treatment outcomes and reduce adverse effects for patients.

Collaborations

Anderson has collaborated with notable coworkers, including Peter S Mezes and Brian B Gourlie, who contribute to the research and development efforts in his field.

Conclusion

W H Anderson's contributions to cancer treatment through his innovative patents highlight the importance of research in biotechnology. His work exemplifies the potential for advancements in medical therapies that can significantly improve patient care.